To the Editor: Dr Traverse and colleagues observed no differences at 6 months in global or regional LV function, infarct size, or infarct volumes in patients with LV dysfunction as a consequence of an MI who received intracoronary infusion of autologous BMCs compared with controls.1 The authors attributed the lack of efficacy when compared with similar trials that found an improvement in LV function in part to the late time of infusion (median: 17.4 days vs 7 days in prior studies) when BMC homing signals from ischemic cardiomyocytes have diminished. We believe the authors did not address a more likely cause for lack of efficacy in their trial: infusion of an insufficient number of potent cells.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.